Femasys, Inc. (FEMY)

NASDAQ: FEMY · IEX Real-Time Price · USD
2.05
+0.14 (7.33%)
At close: Aug 12, 2022 4:00 PM
2.06
+0.01 (0.49%)
After-hours: Aug 12, 2022 4:28 PM EDT
7.33%
Market Cap 24.22M
Revenue (ttm) 1.15M
Net Income (ttm) -10.14M
Shares Out 11.81M
EPS (ttm) -0.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,552
Open 1.95
Previous Close 1.91
Day's Range 1.95 - 2.06
52-Week Range 1.26 - 8.40
Beta n/a
Analysts Buy
Price Target 10.46 (+410.2%)
Earnings Date Aug 10, 2022

About FEMY

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obst... [Read more...]

Industry Medical Instruments & Supplies
IPO Date Jun 18, 2021
Employees 27
Stock Exchange NASDAQ
Ticker Symbol FEMY
Full Company Profile

Financial Performance

In 2021, Femasys's revenue was $1.18 million, an increase of 13.66% compared to the previous year's $1.04 million. Losses were -$7.54 million, 9.01% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for FEMY stock is "Buy." The 12-month stock price forecast is 10.46, which is an increase of 410.24% from the latest price.

Price Target
$10.46
(410.24% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Femasys Inc. (FEMY) Reports Q2 Loss, Tops Revenue Estimates

Femasys Inc. (FEMY) delivered earnings and revenue surprises of 15.38% and 1%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update

ATLANTA, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally inv...

Femasys to Participate in the Women's Health Panel Discussion Presented by Maxim Group LLC and hosted by M-Vest on We...

ATLANTA, July 11, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally inv...

Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2022

- Furthers advancement of much-needed minimally invasive technologies for underserved areas of women's health with pending commercialization of products, FemCerv ® and FemCath ™ expected by year-end

Femasys Inc. to Participate in the M-Vest 2022 Virtual Growth Conference

ATLANTA, March 25, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally in...

Femasys Inc. Announces Financial Results for the Year Ended December 31, 2021

-- Company builds out management team and continues to implement its clinical programs to advance much-needed technologies for women's health -- ATLANTA, March 24, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. ...

Femasys Inc. to Participate in Upcoming January Investor Conferences

ATLANTA, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally inv...

Femasys Inc. to Present at The MedTech Conference

ATLANTA, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally in...

Femasys Inc. To Join the Russell Microcap® Index

ATLANTA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a biomedical company developing a suite of product candidates to transform women's healthcare with m...

Femasys Inc. Announces the Appointment of Edward Evantash, M.D. as Chief Medical Officer

-- Industry veteran with over than two decades of experience in medical affairs to lead clinical and medical affairs at Femasys -- ATLANTA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY)...

Femasys Inc. Announces First Patient Treated in Pivotal Trial for FemaSeed

First in Class Insemination Treatment for Infertility

Chardan Acts as Lead Left Bookrunner in Femasys' $34.45 Million IPO

NEW YORK, June 21, 2021 /PRNewswire/ -- Chardan, a global investment bank, today announced that it acted as lead left bookrunner in the successful closing of the $34.45 million IPO of Femasys, Inc. (NAS...

Peter Thiel's Atai Life Sciences and 5 Other Companies List Shares

Going public on Friday: atai Life Sciences, Ambrx Biopharma, Century Therapeutics, Codex DNA, Cyteir Therapeutics, and Femasys.

Other symbols: ATAIAMAMCYTDNAYIPSC